Insta
Swarajya Staff
Apr 15, 2021, 05:00 PM | Updated 05:00 PM IST
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
India is set to receive Russian Vaccine Sputnik V stocks in this quarter, between April and Jun, which was granted emergency use authorisation (EUA) earlier this week on Monday, 12 April reports Times of India.
After Covishield and Covaxin, Sputnik V became the third Covid-19 vaccine to be used in the country.
As part of its contract with the Russian Direct Investment Fund (RDIF), Hyderabad-based Dr Reddy’s Laboratories (DRL) is expected to receive around 250 million doses of Sputnik V.
DRL has received restricted emergency use permission to supply the vaccine in liquid form, so the company will have to arrange logistics to store and distribute the vaccine at lower temperatures of minus 18°C to minus 22°C, at which its safety and potency can be ensured.
The vaccine is slated to be available in larger quantities in the July-September quarter once the Indian companies that have tied up with RDIF begin manufacturing in the country.
RDIF has agreements with Gland Pharma, Stelis Biopharma, Hetero Biopharma, Panacea Biotec, Virchow Biotech, and Shilpa Medicare to manufacture 850 million doses of Sputnik V in India.